10x Genomics(US:TXG) Prnewswire·2026-01-11 17:00Core Insights - 10x Genomics, Inc. announced preliminary, unaudited financial results for Q4 and full year 2025, highlighting both growth and challenges in revenue streams [1][6]. Financial Results Summary Fourth Quarter 2025 - Revenue for Q4 2025 was approximately $166.0 million, reflecting an 11% sequential growth and a 1% increase year-over-year [6]. - Instruments revenue was about $15.5 million, showing a 29% sequential growth but a 36% decrease compared to the same period last year [6]. - Consumables revenue reached approximately $141.7 million, with an 11% sequential growth and a 6% increase year-over-year [6]. - Services and License and Royalty revenue was approximately $8.8 million, representing a 3% decrease sequentially but a 23% growth year-over-year [6]. Full Year 2025 - Total revenue for the year ended December 31, 2025, was approximately $642.8 million, with a 2% decrease from the prior year when excluding $44.1 million related to patent litigation settlements [6]. - Instruments revenue for the full year was approximately $56.8 million, a 39% decrease from the previous year [6]. - Consumables revenue for the year was approximately $507.2 million, reflecting a 3% growth over the prior year [6]. - Services and License and Royalty revenue was approximately $34.8 million, representing a 41% growth year-over-year when excluding the patent litigation settlements [6]. Operational Highlights - Cumulative sales of Chromium instruments exceeded 6,400, while cumulative Spatial instruments sold surpassed 1,500 by the end of 2025 [6]. - Single Cell consumables reactions sold increased by more than 20% compared to the prior year [6]. - Cash, cash equivalents, and marketable securities totaled approximately $520 million as of December 31, 2025 [6]. Management Commentary - The CEO of 10x Genomics expressed pride in the team's resilience and innovation throughout 2025, emphasizing strengthened customer partnerships and operational discipline [4].